$SUND
Sundance Strategies, Inc.

2023 Q3 Form 10-Q Financial Statement

#000149315223028534 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $92.70K $131.3K $214.0K
YoY Change -42.61% -38.63% -12.12%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $92.70K $44.00K $71.00K
YoY Change -42.61% -38.03% -70.84%
Operating Profit -$92.70K -$131.3K -$214.0K
YoY Change -42.61% -38.63% -12.12%
Interest Expense $108.3K $97.97K $74.14K
YoY Change 42.66% 32.15% 13.39%
% of Operating Profit
Other Income/Expense, Net -$108.3K -$206.9K -$87.64K
YoY Change 21.12% 136.07% -161.61%
Pretax Income -$201.0K -$338.2K -$301.6K
YoY Change -19.91% 12.13% 197.98%
Income Tax
% Of Pretax Income
Net Earnings -$201.0K -$338.2K -$301.6K
YoY Change -19.91% 12.13% 197.98%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 -$0.01 -$0.01
Diluted Earnings Per Share $0.00 -$0.01 -$7.284K
COMMON SHARES
Basic Shares Outstanding 41.41M shares 41.41M shares 41.41M shares
Diluted Shares Outstanding 41.43M shares 41.41M shares 41.41M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $185.0K $6.070K $66.99K
YoY Change 36898.0% -90.94% 253.51%
Cash & Equivalents $185.0K $6.071K $66.99K
Short-Term Investments
Other Short-Term Assets $16.19K $4.740K $4.670K
YoY Change 1283.76% 1.5% -28.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $201.2K $10.81K $71.65K
YoY Change 11982.7% -84.91% 181.32%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.00 -$1.00 -$3.00
YoY Change -40.0% -66.67%
TOTAL ASSETS
Total Short-Term Assets $201.2K $10.81K $71.65K
Total Long-Term Assets $3.00 -$1.00 -$3.00
Total Assets $201.2K $10.81K $71.65K
YoY Change 11946.71% -84.91% 181.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $463.1K $464.4K $585.0K
YoY Change -30.4% -20.61% 5.29%
Accrued Expenses $670.6K $229.6K $381.9K
YoY Change 47.37% -39.87% 50.24%
Deferred Revenue
YoY Change
Short-Term Debt $300.0K $0.00 $300.0K
YoY Change 0.0% -100.0% 0.0%
Long-Term Debt Due $876.0K $0.00 $876.0K
YoY Change 0.0% -100.0% 6.05%
Total Short-Term Liabilities $2.710M $1.094M $2.543M
YoY Change 0.49% -56.98% 8.87%
LONG-TERM LIABILITIES
Long-Term Debt $2.386M $3.511M $2.126M
YoY Change 12.24% 65.18% 10.96%
Other Long-Term Liabilities $965.0K $1.305M $731.5K
YoY Change 27.15% 78.38% 36.53%
Total Long-Term Liabilities $3.351M $4.816M $2.857M
YoY Change 16.16% 68.56% 16.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.710M $1.094M $2.543M
Total Long-Term Liabilities $3.351M $4.816M $2.857M
Total Liabilities $6.061M $5.910M $5.400M
YoY Change 8.59% 9.45% 12.8%
SHAREHOLDERS EQUITY
Retained Earnings -$35.60M -$35.40M -$32.55M
YoY Change 8.53% 8.75%
Common Stock $41.61K $41.41K $41.41K
YoY Change 0.48% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.859M -$5.899M -$5.328M
YoY Change
Total Liabilities & Shareholders Equity $201.2K $10.81K $71.65K
YoY Change 11982.7% -84.91% 181.32%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$201.0K -$338.2K -$301.6K
YoY Change -19.91% 12.13% 197.98%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$90.08K -$106.4K -$201.0K
YoY Change 35.48% -47.04% -33.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 269.0K $112.0K
YoY Change
NET CHANGE
Cash From Operating Activities -90.08K -$106.4K -$201.0K
Cash From Investing Activities
Cash From Financing Activities 269.0K $112.0K
Net Change In Cash 178.9K $5.518K -$201.0K
YoY Change -369.09% -102.75% 8916.6%
FREE CASH FLOW
Cash From Operating Activities -$90.08K -$106.4K -$201.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
usd
CY2023Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001171838
CY2023Q2 dei Amendment Flag
AmendmentFlag
false
CY2023Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2023Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
CY2023Q2 us-gaap Financing Interest Expense
FinancingInterestExpense
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
CY2022Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
CY2022Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q2 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q2 SUND Issued Warrants As Debt Issuance Costs
IssuedWarrantsAsDebtIssuanceCosts
usd
CY2023Q2 us-gaap Financing Interest Expense
FinancingInterestExpense
usd
CY2023Q2 dei Document Type
DocumentType
10-Q
CY2023Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q2 dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q2 dei Entity File Number
EntityFileNumber
000-50547
CY2023Q2 dei Entity Registrant Name
EntityRegistrantName
SUNDANCE STRATEGIES, INC.
CY2023Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0515333
CY2023Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
4626 North 300 West
CY2023Q2 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite No. 365
CY2023Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Provo
CY2023Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
CY2023Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84604
CY2023Q2 dei City Area Code
CityAreaCode
(801)
CY2023Q2 dei Local Phone Number
LocalPhoneNumber
717-3935
CY2023Q2 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023Q2 dei Trading Symbol
TradingSymbol
SUND
CY2023Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q2 dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41408441 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6071 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4740 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
8295 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
10811 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
8848 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
464389 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
753050 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
229622 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
574558 usd
CY2023Q2 SUND Stock Repurchase Payable Current
StockRepurchasePayableCurrent
400000 usd
CY2023Q1 SUND Stock Repurchase Payable Current
StockRepurchasePayableCurrent
400000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1094011 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2903608 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
1304802 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
857685 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4816268 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3139148 usd
CY2023Q2 us-gaap Liabilities
Liabilities
5910279 usd
CY2023Q1 us-gaap Liabilities
Liabilities
6042756 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41408441 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41408441 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41408441 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41408441 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
41409 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
41409 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
29459190 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
28986558 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35400067 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35061875 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5899468 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6033908 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10811 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8848 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
131299 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
213957 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-131299 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-213957 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-398920 usd
CY2023Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
290000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
97973 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
74139 usd
CY2022Q2 us-gaap Financing Interest Expense
FinancingInterestExpense
13500 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-206893 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-87639 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-338192 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-301596 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-338192 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-301596 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41408441 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41408441 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41408441 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41408441 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5026867 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-301596 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5328463 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6033908 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6033908 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
73712 usd
CY2023Q2 SUND Warrants Issued In Connection To Extinguishment Of Debt
WarrantsIssuedInConnectionToExtinguishmentOfDebt
398920 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-338192 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5899468 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5899468 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-338192 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-301596 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-398920 usd
CY2023Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
290000 usd
CY2023Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
15765 usd
CY2023Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3555 usd
CY2022Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3500 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1339 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3988 usd
CY2023Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
102181 usd
CY2022Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
93128 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-106432 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-200980 usd
CY2023Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
111950 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
111950 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5518 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-200980 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
553 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
267966 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6071 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66986 usd
CY2023Q2 SUND Issued Warrants As Debt Issuance Costs
IssuedWarrantsAsDebtIssuanceCosts
73712 usd
CY2023Q2 us-gaap Basis Of Accounting
BasisOfAccounting
<p id="xdx_846_eus-gaap--BasisOfAccounting_zw8TxTzAeux5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zZHz0W8nDrZh">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting and reflect the financial position, results of operations and cash flows of the Company. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, these unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, which was filed with the SEC on June 29, 2023. The results from operations for the three-month period ended June 30, 2023, are not necessarily indicative of the results that may be expected for the fiscal year ended March 31, 2024. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, stockholders’ equity, and cash flows at June 30, 2023 and for all periods presented herein have been made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosure of contingent amounts in the Company’s financial statements and the accompanying notes. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10170544 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7250241 shares
CY2023Q2 SUND Liquidity Requirements And Going Concern Disclosure Textblock
LiquidityRequirementsAndGoingConcernDisclosureTextblock
<p id="xdx_801_ecustom--LiquidityRequirementsAndGoingConcernDisclosureTextblock_zTXCTkbiKzde" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2) <span id="xdx_82D_z5xQecWb434f">LIQUIDITY REQUIREMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the Company’s inception on January 31, 2013, its operations have been primarily financed through sales of equity, debt financing from related parties and the issuance of notes payable and convertible debentures. As of June 30, 2023, the Company had $<span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20230630_zeMtX3MVgH65" title="Cash">6,071</span> of cash assets, compared to $<span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20230331_zWztmWrOsHy5" title="Cash">553</span> as of March 31, 2023. As of June 30, 2023, the Company had access to draw an additional $<span id="xdx_903_eus-gaap--NotesPayable_iI_pp0p0_c20230630_zcmx6bLjPel2" title="Notes payable">4,299,942</span> on the notes payable, related party (see Note 6) and $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebentureAgreementMember_zyh6RimnPC1h" title="Debt borrowing amount">3,000,000</span> on the Convertible Debenture Agreement (See Note 7). For the three months ended June 30, 2023, the Company’s average monthly operating expenses were approximately $<span id="xdx_907_eus-gaap--OperatingExpenses_pp0p0_c20230401__20230630_zFAdl6GWnwTb" title="Operating Expenses">44,000</span>, which includes salaries of the Company’s employee, consulting agreements and contract labor, general and administrative expenses and legal and accounting expenses. In addition to the monthly operating expenses, the Company continues to pursue other debt and equity financing opportunities, and as a result, financing expenses of $<span id="xdx_90F_eus-gaap--FinancingInterestExpense_pp0p0_dxL_c20230401__20230630_z2kLxTTzaRCf" title="Financing Interest Expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0378">0</span></span> and $<span id="xdx_901_eus-gaap--FinancingInterestExpense_pp0p0_c20220401__20220630_zZTXkarlDbqe" title="Financing Interest Expense">13,500</span> were incurred during the three months ended June 30, 2023, and 2022, respectively. As management continues to explore additional financing alternatives, beginning July 1, 2023, the Company is expected to spend up to an additional $<span id="xdx_900_ecustom--AdditionalFinancingAlternatives_pp0p0_c20230401__20230630_zoAaWt20Ejlg" title="Additional financing alternatives">300,000</span> on these efforts. Outstanding Accounts Payable as of June 30, 2023, totaled $<span id="xdx_903_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20230630_z74lFg0G0Baf" title="Accounts payable">464,389</span>. Management has concluded that its existing capital resources and availability under its existing convertible debentures and debt agreements with related parties will be sufficient to fund its operating working capital requirements for at least the next 12 months from the issuance of these financial statements, or through August 2024. Related parties have given assurance that their continued support, by way of either extensions of due dates, or increases in lines-of-credit, can be relied on. As mentioned above, the Company also continues to evaluate other debt and equity financing opportunities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The recent outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a going concern basis under which the Company is expected to be able to realize its assets and satisfy its liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6071 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
4299942 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
44000 usd
CY2022Q2 us-gaap Financing Interest Expense
FinancingInterestExpense
13500 usd
CY2023Q2 SUND Additional Financing Alternatives
AdditionalFinancingAlternatives
300000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
464389 usd
CY2018Q4 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
8000000 shares
CY2018Q4 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
300000 usd
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.05
CY2022Q2 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.05
CY2021Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08 pure
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
332947 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2633332 shares
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
124225 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
124225 usd
CY2023Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
290000 usd

Files In Submission

Name View Source Status
0001493152-23-028534-index-headers.html Edgar Link pending
0001493152-23-028534-index.html Edgar Link pending
0001493152-23-028534.txt Edgar Link pending
0001493152-23-028534-xbrl.zip Edgar Link pending
ex10-40.htm Edgar Link pending
ex10-40_001.jpg Edgar Link pending
ex10-45.htm Edgar Link pending
ex10-45_001.jpg Edgar Link pending
ex10-46.htm Edgar Link pending
ex10-46_001.jpg Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sund-20230630.xsd Edgar Link pending
sund-20230630_cal.xml Edgar Link unprocessable
sund-20230630_def.xml Edgar Link unprocessable
sund-20230630_lab.xml Edgar Link unprocessable
sund-20230630_pre.xml Edgar Link unprocessable